ArticleOncology letters2019
Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 12 citations in OpenAlex.
- Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma.Blood cancer journal · 2026Article
- Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication-A Systematic Review.Cancers · 2025Review
- Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1.Cancer immunology, immunotherapy : CII · 2025Article
- The Imidazacridine Derivative LPSF/AC-05 Induces Apoptosis, Cell Cycle Arrest, and Topoisomerase II Inhibition in Breast Cancer, Leukemia, and Lymphoma.Current cancer drug targets · 2025Article
- PK/PD Evaluation of Antibody-Drug Conjugates with Enhanced Immune Effector Functions.The AAPS journal · 2024Article
- Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used.Annals of laboratory medicine · 2022Article
- Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma.International journal of molecular sciences · 2022Review
- Therapeutic strategies for gastric cancer targeting immune cells: Future directions.Frontiers in immunology · 2022Review
- Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies.Cancers · 2021Review
- Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Review
- Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.Frontiers in immunology · 2020Article
- Complement system in Anti-CD20 mAb therapy for cancer: A mini-review.International journal of immunopathology and pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence indicates that the anti-CD20 monoclonal antibody rituximab significantly improves the clinical prognosis of patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, a number of patients relapse or fail to respond to rituximab. To further understand the cause of this, polymorphisms of FcγRIIIa were initially detected in healthy volunteers. Subsequently, the rituximab-dependent natural killer (NK) cell-mediated cytotoxicity of different FcγRIIIa genotypes was assessed by a cytotoxicity assay
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.